Vorasidenib | Isocitrate dehydrogenase 1/2 inhibitor
Available Options
| Size: | Price | Quantity | |
|---|---|---|---|
| 5 mg | $75.00 | ||
| 25 mg | $280.00 |
Vorasidenib (1644545-52-7) is a highly potent (IC50’s = 7 nM IDH2-R140Q, 0.6 nM IDH1-R132H/WT, and 0.25 nM Neurosphere TS603 IDH1-R132H), selective, and brain-penetrant inhibitor of mutant isocitrate dehydrogenase 1 and 2 (IDH1/2).1 It led to >97% inhibition of 2-hydroxyglutarate production in mIDH1 glioma tissue. Vorasidenib significantly improved progression-free survival and delayed time to next intervention in a phase 3 glioma trial.2
References/Citations:
- Konteatis et al. (2020), Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of Glioma; ACS Chem. Lett. 11 101
- Mellinghoff et al. (2023), Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma; N. Engl. J. Med. 389 589
C14H13ClF6N6
>98% HPLC
NMR: (Conforms)
Safety Data Sheet:
Product Data Sheet:
Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee
Vorasidenib (1644545-52-7) is a highly potent (IC50’s = 7 nM IDH2-R140Q, 0.6 nM IDH1-R132H/WT, and 0.25 nM Neurosphere TS603 IDH1-R132H), selective, and brain-penetrant inhibitor of mutant isocitrate dehydrogenase 1 and 2 (IDH1/2).1 It led to >97% inhibition of 2-hydroxyglutarate production in mIDH1 glioma tissue. Vorasidenib significantly improved progression-free survival and delayed time to next intervention in a phase 3 glioma trial.2
References/Citations:
- Konteatis et al. (2020), Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of Glioma; ACS Chem. Lett. 11 101
- Mellinghoff et al. (2023), Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma; N. Engl. J. Med. 389 589
Related products
-
Ibrutinib | BTK inhibitor
From $40.00CAS:936563-96-1Catalog Number:10-4757Alternate Name:PCI-32765Activity:BTK inhibitor/Cancer immunotherapy enhancerChemical Name:1-[(3R)-3-[4-Amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-oneMolecular Weight:440.51Molecular Formula:C25H24N6O2Solubility:Soluble in DMSO ( up to at least 25 mg/ml)Physical Properties:White or off-white solidPurity:99% by HPLC
NMR (Conforms)Storage Temperature:-20°CStability:Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months.Shipping Code:RT -
Acalabrutinib | Highly selective BTK inhibitor
From $45.00CAS:1420477-60-6Catalog Number:10-4806Alternate Name:ACP-196Activity:Highly selective BTK inhibitorChemical Name:4-[8-Amino-3-[(2S)-1-but-2-ynoylpyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl]-N-pyridin-2-ylbenzamideMolecular Weight:465.52Molecular Formula:C26H23N7O2Solubility:Soluble in DMSO (up to at least 25 mg/ml)Physical Properties:Yellow solidPurity:98% by HPLC
NMR (Conforms)Storage Temperature:-20°CStability:Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months.Shipping Code:RT -
Norfluoxetine HCl | Fluoxetine Metabolite
From $60.00CAS:57226-68-3Catalog Number:10-2671Alternate Name:DesmethylfluoxetineActivity:Fluoxetine metaboliteChemical Name:3-Phenyl-3-(4-trifluoromethyl-phenoxy)-propylamine hydrochloride (racemic)Molecular Weight:331.76Molecular Formula:C16H16F3NO HClSolubility:Soluble in DMSO ( up to at least 25 mg/ml)Physical Properties:Beige waxy solidPurity:98% by TLC
NMR (Conforms)Storage Temperature:-20°CStability:Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months.Shipping Code:RT
Calculate the molar concentration, mass or volume in a solution.
Concentration × Volume × Molecular Weight = Mass
